Printer Friendly

Affymetrix and Incyte settle suits. (Executive Briefing: news, trends & market intelligence for instrument executives).

Palo Alto, CA and Santa Clara, CA 12/21/01--Affymetrix and Incyte Genomics have announced a settlement that ends all current infringement litigation between the two companies. Under the settlement, the two companies will cross license each other's intellectual property. Financial terms were not disclosed. The series of lawsuits began in 1998 when Affymetrix sued Incyte for infringement on five patents related to microarray technology. In 2000, Incyte filed a counter lawsuit alleging infringement on two of its RNA amplification patents. The companies stated that they are also considering future commercial agreements.

Incyte's incentive to settle these suits is its recent effort to restructure, which includes no longer manufacturing microarrays. Affymetrix already this year settled suits with Hyseq and Oxford Gene Technology, perhaps reflecting are organization of the company's priorities that emphasize immediate profitability and new partnerships over litigation.
COPYRIGHT 2001 Strategic Directions International Inc. (SDI)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Incyte Genomics
Comment:Affymetrix and Incyte settle suits. (Executive Briefing: news, trends & market intelligence for instrument executives).(Incyte Genomics)
Publication:Instrument Business Outlook
Article Type:Brief Article
Geographic Code:1USA
Date:Dec 31, 2001
Previous Article:The 2001 IBO stock market indices: a mixed market.
Next Article:Danaher acquires Viridor. (Executive Briefing: news, trends & market intelligence for instrument executives).

Related Articles
Incyte granted motion to transfer in lawsuit filed by Affymetrix.
Incyte Prevails on Preliminary Injunction Request.
Random Samples.
Incyte introduces Agilent human gene expression microarrays.
Affymetrix advances in Incyte litigation.
Affymetrix and Incyte settle all patent litigation.
Cambridge Anitbody Technology gains access to Incyte cDNA clone database.
Litigation. (Random Samples).

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters